Total raised
—
Last: Seed 2017-11
Stage
Seed
Founded
2017
Headcount
6
HQ
Yokne'am Illit
Sector
Health Tech & Life Sciences
About
NeurOptic's lead product for glaucoma is based on an FDA-approved drug indicated as therapy for neurodegenerative disease. NeurOptic is developing an ophthalmic formulation for glaucoma treatment established on the prolonged residence time of a monoamine oxidase inhibitor on the ocular surface and providing sustained delivery and constant effect of the drug for two months. Preliminary pre-clinical studies showed that the novel topical treatment of NeurOptic's product exerted a significant effect on high levels of intraocular pressure and may prevent neuronal damage in the eye.
Funding history · 1 round · — total
2017-11
Seed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is NeurOptic's primary focus in product development?
- NeurOptic is developing an ophthalmic formulation for glaucoma treatment, based on an FDA-approved drug for neurodegenerative disease.
- When was NeurOptic founded?
- NeurOptic was founded in April 2017.
- What is the current operational status of NeurOptic?
- NeurOptic is currently inactive, having ceased operations in April 2018.
- Where is NeurOptic's headquarters located?
- NeurOptic's headquarters is in Yokne'am Illit, Israel.
- What was NeurOptic's last known funding round?
- NeurOptic completed a Seed round in November 2017, with Youdim Pharmaceuticals as an investor.
- What is the intended mechanism of NeurOptic's glaucoma treatment?
- NeurOptic's treatment aims for sustained delivery and constant effect of a monoamine oxidase inhibitor on the ocular surface for two months.
- What were the results of NeurOptic's preliminary pre-clinical studies?
- Preliminary pre-clinical studies indicated that NeurOptic's novel topical treatment significantly affected high levels of intraocular pressure and may prevent neuronal damage in the eye.
- How many employees did NeurOptic have?
- NeurOptic had 6 employees.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2C
Highlights
1 Patents
Tags
pharma-companiesglaucomaeye-diseasesophthalmologypharmaceuticals